A recent EY report points out that 50% of Indian pharma companies are in the process of investing in or considering AI-solution-driven innovations, while 25% have already implemented Generative AI (GenAI) applications in manufacturing. Indian pharma is at the forefront of AI adoption in Indian healthcare, deploying AI in drug discovery, supply chain management, and manufacturing efficiency.

Key Highlights
AI Adoption in Indian Pharma Industry:

• 50% of pharma companies are investing in AI-based projects.

• 25% of companies have already deployed GenAI applications in manufacturing.

• AI adoption is likely to deliver 30-40% productivity improvements.

Pharma Operations Where AI is Revolutionizing:

• Drug Discovery & Regulatory Submissions: GenAI tools are being utilized to streamline drug discovery and accelerate regulatory approvals.

• Manufacturing & Supply Chain Efficiency: Production improvements driven by AI are enhancing product quality and operational effectiveness.

• Commercial & Market Analysis: AI applications are evaluating market trends and providing data-driven insights to healthcare providers.

Industry-Wide AI Integration:

• 50% of the companies polled are implementing AI in customer support, manufacturing, supply chain, and operations.

• 25% of companies are focused on AI in procurement optimization.

• 75% of the adopters of AI claimed cost savings and improved customer satisfaction from AI-enabled automation.

Alignment with National Economic Growth:
The Economic Survey (FY2024-25) pointed out that 34% of Indian healthcare organizations are testing AI projects, with 16% pushing GenAI initiatives into full-scale production.

Industry Leader Statements:
Suresh Subramanian, National Lifesciences Leader, EY-Parthenon India:
"The pharma sector is quickly adopting GenAI, with 50% of companies investing in or considering AI-driven solutions, and 25% already utilizing AI applications in production."As the adoption of AI gains pace in the Indian pharmaceutical industry, the companies are boosting operational efficiency, enhancing research abilities, and decreasing costs. As major AI-based changes occur in drug discovery, production, and customer interactions, the sector is on the verge of rapid digital transformation. The future will witness more integration of AI into clinical trials, regulatory guidelines, and customized medicine.